NYX-2925 Lowers Marker of Pain Severity in Fibromyalgia Patients, Early Phase 2 Trial Results Show

NYX-2925 Lowers Marker of Pain Severity in Fibromyalgia Patients, Early Phase 2 Trial Results Show
The chronic pain treatment candidate NYX-2925 lowered levels of a brain activity marker called glutamine (Glx), associated with pain severity, according to preliminary results of a Phase 2 pilot trial in patients with moderate to severe fibromyalgia. The findings also showed improvement in patient-reported pain, as well as a reduction in fibromyalgia’s impact on daily living, and less anxiety, depression, and cognitive impairment. Aptinyx’s NYX-2925 is a modulator of N-methyl-D-aspartate (NMDA) receptors, key in excitatory nerve transmission mediated by the neurotransmitter glutamate and are dysfunctional in several nervous system disorders. When pain becomes chronic, it is largely mediated by central learning and memory processes. The investigational compound increases neural cell communication, which Aptynx believes is uniquely suited to treat chronic pain. A Phase 1 study (NCT02834741) in healthy subjects showed that NYX-2925 was well-tolerated across a wide dose range. The exploratory phase 2 study (NCT03249103) is evaluating the efficacy and safety of daily oral treatment with 20 mg and 200 mg of NYX-2925 as well as a placebo over six weeks. During the study, patients have functional magnetic resonance imaging scans combined with an approach called proton magnetic resonance spectroscopy to assess brain activity markers (primary outcome) associated with central sensitization of pain, which is key in chronic pain. Secondary outcomes include average daily pain and
Subscribe or to access all post and page content.